If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Wendy Greengross (29 April 1925 – 10 October 2012); author of books on pastoral care and counselling, journalist, general practitioner and broadcaster. The Independent called her "a pioneering counsellor and one of the leading figures in fighting for equal rights for the disabled and the elderly"; went into broadcasting, joining BBC Radio 4 counselling programme If You Think You've Got Problems; also had her own television show on BBC1, Let's Talk it Over; father was mayor of Holborn, and brother Sir Alan Greengross (born 1929) was Conservative member of Greater London Council. Tony Greenstein (born December 1953) is a left-wing anti-fascist, anti-Zionist writer activist, whose father came from a rabbinical family. Author of The Fight Against Fascism in Brighton & the South Coast, Zionism: Antisemitism's twin in Jewish garb and Zionism During the Holocaust: Weaponising Memory in the Service of State and Nation. John Hajnal (born Hajnal-Kónyi; 26 November 1924 – 30 November 2008), was Hungarian-British academic in fields of mathematics and economics (statistics); author of numerous monographs and academic papers and a book on the inefficacy of the British education system “The student trap: A critique of university and sixth-form curricula”; best known for identifying, in landmark 1965 paper, the historical pattern of marriage of northwest Europe in which people married late and many adults remained single.
The superficial layer of transitional epithelium is connected to the basal layer via cellular projections, such as intermediate filaments protruding from the cellular membrane. These structural elements cause the epithelium to allow distension; however, these also cause the tissue to be relatively fragile and, therefore, difficult to study.
== History == In 1902 Victor Henri proposed a quantitative theory of enzyme kinetics, but at the time the experimental significance of the hydrogen ion concentration was not yet recognized. After Peter Lauritz Sørensen had defined the logarithmic pH-scale and introduced the concept of buffering in 1909, the German chemist Leonor Michaelis and Dr. Maud Leonora Menten (a postdoctoral researcher in Michaelis's lab at the time) repeated Henri's experiments and confirmed his equation, which is now generally referred to as Michaelis-Menten kinetics (sometimes also Henri-Michaelis-Menten kinetics). Their work was further developed by G. E. Briggs and J. B. S. Haldane, who derived kinetic equations that are still widely considered today a starting point in modeling enzymatic activity. The major contribution of the Henri-Michaelis-Menten approach was to think of enzyme reactions in two stages. In the first, the substrate binds reversibly to the enzyme, forming the enzyme-substrate complex. This is sometimes called the Michaelis complex. The enzyme then catalyzes the chemical step in the reaction and releases the product. The kinetics of many enzymes is adequately described by the simple Michaelis-Menten model, but all enzymes have internal motions that are not accounted for in the model and can have significant contributions to the overall reaction kinetics. This can be modeled by introducing several Michaelis-Menten pathways that are connected with fluctuating rates, which is a mathematical extension of the basic Michaelis Menten mechanism.
If performed without consideration for potential local environmental impacts, aquaculture in inland waters can result in more environmental damage than wild fisheries, though with less waste produced per kg on a global scale. Local concerns with aquaculture in inland waters may include waste handling, side-effects of antibiotics, competition between farmed and wild animals, and the potential introduction of invasive plant and animal species, or foreign pathogens, particularly if unprocessed fish are used to feed more marketable carnivorous fish. If non-local live feeds are used, aquaculture may introduce exotic plants or animals with disastrous effects. Improvements in methods resulting from advances in research and the availability of commercial feeds has reduced some of these concerns since their greater prevalence in the 1990s and 2000s . Fish waste is organic and composed of nutrients necessary in all components of aquatic food webs. In-ocean aquaculture often produces much higher than normal fish waste concentrations. The waste collects on the ocean bottom, damaging or eliminating bottom-dwelling life. Waste can also decrease dissolved oxygen levels in the water column, putting further pressure on wild animals. An alternative model to food being added to the ecosystem, is the installation of artificial reef structures to increase the habitat niches available, without the need to add any more than ambient feed and nutrient. This has been used in the "ranching" of abalone in Western Australia.
The Haitian Revolution began in 1791, just before the French Revolutionary Wars, and continued until 1804. France's defeat resulted in the independence of Saint-Domingue and led Napoleon to sell the territory making up the Louisiana Purchase to the United States.
Sources: en.wikipedia.org
Agonists Chaetochromin (4548-G05) Insulin-like growth factor 1 Insulin-like growth factor 2 Insulin Insulin aspart Insulin degludec Insulin detemir Insulin glargine Insulin glulisine Insulin lispro Mecasermin Mecasermin rinfabate Antagonists BMS-754807 S661 S961 Kinase inhibitors Linsitinib Antibodies Xentuzumab (against IGF-1 and IGF-2)
Although orphan disease populations are the smallest, the cost of per-patient outlays among them are the largest and are expected to increase as more people with rare diseases become eligible for subsidies – in the U.S., for example, through the Affordable Care Act.
=== Blood supply === Branches of the internal pudendal arteries are the main arterial supply. The dorsal arteries of the penis run alongside the dorsal vein between the corpora cavernosa and supply the fibrous tissue surrounding them, the corpus spongiosum, the spongy urethra and the penile skin. The deep arteries of the penis run in the centre of each corpus cavernosum and supply the erectile tissue; their branches, the helicine arteries, are coiled when the penis is flaccid. The penile skin is also supplied by superficial and deep branches of the external pudendal arteries. The deep dorsal vein of the penis receives blood from a venous plexus draining the cavernous spaces, while the superficial dorsal vein drains the skin and subcutaneous tissue.
==== Adsorption ==== Adsorption is a mass transfer process in which a substance is transported from the liquid phase to the surface of a solid/liquid (adsorbent) and becomes physically and chemically bonded (adsorbate). Adsorption can be classified into two forms based on the type of attraction between the adsorbate and the adsorbent: physical and chemical adsorption, commonly known as physisorption and chemisorptions.
Sources: en.wikipedia.org
Advanced characterization of bacterial organisms can be also performed, allowing to obtain the necessary depth and breadth of coverage for genetic characterization results. Gene calling can be performed in a variety of ways, including RAST or using NCBI services at the time of full genome submission. Results of multiple annotation tools can be compared for accuracy and completeness and, if necessary, merged using BEACON. For characterization of antibiotic resistance genes, the Resistance Gene Identifier from the Comprehensive Antibiotic Resistance Database (CARD) is commonly used. To characterize virulence factor genes, ShortBRED offers analyses with a customized database from the Virulence Factor Database.
riboswitch A regulatory sequence within a messenger RNA transcript that can bind a small effector molecule, preventing or disrupting translation and thereby acting as a switch that regulates the mRNA's expression.
=== Pharmacokinetics === The oral bioavailability of setipiprant is 44% in rats and 55% in dogs, which suggests that it should be orally bioavailable in humans. The half-life of setipiprant in humans is about 11 hours. The maximum concentration in plasma (Cmax) is 6.04 and 6.44 mcg/mL for setipiprant tablets and capsules respectively, with an area under the curve of 31.88 and 31.50 mcg×hours/mL for setipiprant tablets and capsules respectively. Cmax was reached between 1.8–4 hours after oral administration. The tablet and capsule formulations are bioequivalent.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.